宜明昂科获FDA批准开展新药IMM2510临床试验

财中社
02 Jul

  7月2日,宜明昂科(01541)发布公告,宣布其与Instil Bio, Inc.的全资附属公司Axion Bio, Inc.共同开发的IMM2510/AXN-2510获得美国FDA批准进行新药临床试验(IND)。该临床试验预计将于2025年底前启动,旨在评估IMM2510/AXN-2510作为单药治疗复发性或难治性实体肿瘤患者的安全性、疗效、药物代谢动力学及药效学。

  IMM2510/AXN-2510是一种PD-L1和VEGF的双特异性抗体,正在开发用于多种实体肿瘤的治疗。与其他PD-(L)1xVEGF双特异性抗体相比,该药物在VEGF阻断方面具有优势,能够结合多种VEGF受体配体,并通过增强的抗体依赖性细胞毒性直接杀死PD-L1阳性的肿瘤细胞。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10